The oncology market includes a large number of heterogeneous indications demonstrating a wide range of unmet medical needs and incidence rates. Standard treatments for the various forms of cancer include surgery, chemotherapy, radiation therapy and hormone treatment. However, new biological products hold the most promise for changing treatment paradigms. Drugs such as therapeutic antibodies allow for highly specific targeting of cancer cells or signaling molecules in order to reduce unwanted side effects.
MorphoSys is currently developing three proprietary cancer compounds in clinical trials.
MOR202, a fully human HuCAL-based antibody against CD38, a therapeutic target for the treatment of multiple myeloma and potentially certain leukemias.
The second proprietary development program MorphoSys is pursuing in this area is MOR208 (XmAb®5574). The antibody, which targets CD19, is being developed for the treatment of B cell malignancies.
MorphoSys´s most recent cancer antibody is MOR209/ES414, a bispecific anti-PSMA/anti-CD3 antibody against prostate cancer.